We are live on ! Find out more
IAM

Innovis Asset Management Portfolio holdings

AUM $260M
1-Year Est. Return 28.13%
This Fund
S&P 500
This Quarter Est. Return
+10.77%
1 Year Est. Return
+28.13%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$271M
AUM Growth
+$24.2M
Cap. Flow
+$3.94M
Cap. Flow %
1.45%
Top 10 Hldgs %
35%
Holding
186
New
25
Increased
37
Reduced
82
Closed
24

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$4.52M
2
ROK icon
Rockwell Automation
ROK
+$4.16M
3
NEM icon
Newmont
NEM
+$3.45M
4
EMR icon
Emerson Electric
EMR
+$3.41M
5
MSFT icon
Microsoft
MSFT
+$2.94M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$5.32M
2
FCX icon
Freeport-McMoran
FCX
+$3.32M
3
CTVA icon
Corteva
CTVA
+$3.26M
4
DVN icon
Devon Energy
DVN
+$3.24M
5
UNH icon
UnitedHealth
UNH
+$2.68M

Sector Composition

Rank Sector Weight
1 Technology 31.6%
2 Healthcare 22.77%
3 Financials 8.72%
4 Energy 6.58%
5 Consumer Staples 6.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ETNB
151
DELISTED
89bio
ETNB
$198K 0.07%
+10,437
New +$183K
IOVA icon
152
Iovance Biotherapeutics
IOVA
$2.65B
$187K 0.07%
26,512
+128
+0.5% +$916
EYPT icon
153
EyePoint Inc
EYPT
$1.17B
$166K 0.06%
+19,031
New +$116K
NRIX icon
154
Nurix Therapeutics
NRIX
$2.63B
$156K 0.06%
15,648
-14,397
-48% -$147K
AUTL
155
Autolus Therapeutics
AUTL
$543M
$150K 0.06%
63,179
-62,927
-50% -$149K
EVLV icon
156
Evolv Technologies
EVLV
$1.1B
$150K 0.06%
25,020
-63,058
-72% -$298K
GRPN icon
157
Groupon
GRPN
$977M
$133K 0.05%
22,490
-86,746
-79% -$384K
BRCC icon
158
BRC Inc
BRCC
$246M
$117K 0.04%
22,696
-65,886
-74% -$348K
TRVI icon
159
Trevi Therapeutics
TRVI
$2.56B
$103K 0.04%
43,232
-44,137
-51% -$111K
MPAA icon
160
Motorcar Parts of America
MPAA
$261M
$96.6K 0.04%
12,485
-533
-4% -$3.04K
AIOT
161
PowerFleet Inc
AIOT
$583M
$88.7K 0.03%
29,564
+148
+0.5% +$445
GBIO
162
DELISTED
Generation Bio
GBIO
$55.1K 0.02%
1,002
-986
-50% -$45.2K
ASPN icon
163
Aspen Aerogels
ASPN
$523M
– –
-14,413
Closed -$107K
ATEN icon
164
A10 Networks
ATEN
$1.98B
– –
-10,404
Closed -$161K
AUPH icon
165
Aurinia Pharmaceuticals
AUPH
$2.03B
– –
-27,410
Closed -$300K
BRKL
166
DELISTED
Brookline Bancorp
BRKL
– –
-25,090
Closed -$263K
CFG icon
167
Citizens Financial Group
CFG
$30.6B
– –
-7,139
Closed -$217K
CROX icon
168
Crocs
CROX
$6.61B
– –
-1,929
Closed -$244K
CTVA icon
169
Corteva
CTVA
$51.3B
– –
-54,070
Closed -$3.26M
DVN icon
170
Devon Energy
DVN
$47.8B
– –
-64,035
Closed -$3.24M
EOSE icon
171
Eos Energy Enterprises
EOSE
$1.47B
– –
-66,488
Closed -$171K
FCX icon
172
Freeport-McMoran
FCX
$97B
– –
-81,168
Closed -$3.32M
FNKO icon
173
Funko
FNKO
$336M
– –
-21,733
Closed -$205K
HBNC icon
174
Horizon Bancorp
HBNC
$1.05B
– –
-27,171
Closed -$301K
INBK icon
175
First Internet Bancorp
INBK
$255M
– –
-15,447
Closed -$257K
4 5 6
7
8

Similar funds

RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return
PWM
PRW Wealth Management Quincy, Massachusetts $262M AUM 22.64% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return

Innovis Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Innovis Asset Management held 186 positions worth $271M, up 9.8% from $247M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Innovis Asset Management's Q2 2023 filing shows 25 new, 37 increased, 82 reduced and 24 closed positions. Its largest new stake was DexCom: 37,345 shares worth $4.8M. The largest sale was Pfizer, an estimated $5.32M.

By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 29% a quarter earlier, followed by Healthcare and Financials.

  • Innovis Asset Management's largest Q2 2023 buy was DexCom: 37,345 shares worth $4.8M.
  • Innovis Asset Management added most to Newmont in Q2 2023, an estimated $3.45M increase.
  • Innovis Asset Management's biggest Q2 2023 reduction was Pfizer, cutting an estimated $5.32M.
  • Innovis Asset Management fully exited Freeport-McMoran in Q2 2023, selling an estimated $3.32M.
  • Innovis Asset Management's ten largest holdings make up 35% of its $271M portfolio in Q2 2023.
  • Innovis Asset Management opened 25 new positions and closed 24 in Q2 2023.
  • Innovis Asset Management's portfolio value rose 9.8% quarter-over-quarter to $271M.

Based on Innovis Asset Management's 13F filing for Q2 2023, filed 3 Aug 2023.